Divis Labs Chippada facility gets zero USFDA observations

"This is to inform you that the Company's Unit-II at Village Chippada, Bheemunipatnam District, Andhra Pradesh has had an inspection by the US Food and Drug Administration (US-FDA) from 27 January 2020 to 31 January, 2020. The inspection has been concluded with no "483" observations," Divis said in a BSE filing.

New Delhi: Drugmaker, Divis Laboratories Limited recently informed the bourses that the company has successfully cleared the inspection conducted by the US health regulator at its Unit-II at Village Chippada, Bheemunipatnam District, Andhra Pradesh.

Also Read: Divis Labs Gets No USFDA Observations For Unit-I Telangana Facility

The inspection at the facility was conducted by the US Food and Drug Administration (US-FDA) from 27 January 2020 to 31 January 2020. The inspection concluded without any observations and no Form 483 was issued.

"This is to inform you that the Company's Unit-II at Village Chippada, Bheemunipatnam District, Andhra Pradesh has had an inspection by the US Food and Drug Administration (US-FDA) from 27 January 2020 to 31 January 2020. The inspection has been concluded with no "483" observations," Divis said in a BSE filing.

Also Read: Divis Lab Vizag Unit Gets USFDA EIR With 6 Observations